CN111615383A - 药物组合物、贴剂及其制备方法、镇痛方法、应用 - Google Patents
药物组合物、贴剂及其制备方法、镇痛方法、应用 Download PDFInfo
- Publication number
- CN111615383A CN111615383A CN201980008813.6A CN201980008813A CN111615383A CN 111615383 A CN111615383 A CN 111615383A CN 201980008813 A CN201980008813 A CN 201980008813A CN 111615383 A CN111615383 A CN 111615383A
- Authority
- CN
- China
- Prior art keywords
- pain
- skin
- pharmaceutical composition
- recess
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 132
- 238000002360 preparation method Methods 0.000 title claims abstract description 41
- 238000000034 method Methods 0.000 title claims abstract description 21
- 230000000202 analgesic effect Effects 0.000 title abstract description 32
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical group CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims abstract description 83
- 229960004194 lidocaine Drugs 0.000 claims abstract description 78
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 48
- 230000003444 anaesthetic effect Effects 0.000 claims abstract description 42
- 239000004480 active ingredient Substances 0.000 claims abstract description 36
- 229960002372 tetracaine Drugs 0.000 claims abstract description 24
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims abstract description 24
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960003150 bupivacaine Drugs 0.000 claims abstract description 10
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960001747 cinchocaine Drugs 0.000 claims abstract description 8
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960001807 prilocaine Drugs 0.000 claims abstract description 5
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims abstract description 5
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 claims abstract description 4
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 claims abstract description 4
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960003831 articaine Drugs 0.000 claims abstract description 4
- 229960005274 benzocaine Drugs 0.000 claims abstract description 4
- 229960003976 etidocaine Drugs 0.000 claims abstract description 4
- 229960004288 levobupivacaine Drugs 0.000 claims abstract description 4
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 claims abstract description 4
- 229960002409 mepivacaine Drugs 0.000 claims abstract description 4
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960004919 procaine Drugs 0.000 claims abstract description 4
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960001549 ropivacaine Drugs 0.000 claims abstract description 4
- 229940072040 tricaine Drugs 0.000 claims abstract description 3
- FQZJYWMRQDKBQN-UHFFFAOYSA-N tricaine methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=CC([NH3+])=C1 FQZJYWMRQDKBQN-UHFFFAOYSA-N 0.000 claims abstract description 3
- 208000002193 Pain Diseases 0.000 claims description 135
- 230000036407 pain Effects 0.000 claims description 135
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 84
- 239000013039 cover film Substances 0.000 claims description 45
- 239000010408 film Substances 0.000 claims description 45
- 239000003814 drug Substances 0.000 claims description 33
- 230000004888 barrier function Effects 0.000 claims description 32
- 238000003860 storage Methods 0.000 claims description 30
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 23
- 208000007514 Herpes zoster Diseases 0.000 claims description 23
- 229920002472 Starch Polymers 0.000 claims description 17
- 239000008107 starch Substances 0.000 claims description 17
- 235000019698 starch Nutrition 0.000 claims description 17
- 229920006255 plastic film Polymers 0.000 claims description 16
- 239000002985 plastic film Substances 0.000 claims description 16
- 208000004983 Phantom Limb Diseases 0.000 claims description 15
- 206010056238 Phantom pain Diseases 0.000 claims description 15
- 230000035699 permeability Effects 0.000 claims description 13
- 239000000375 suspending agent Substances 0.000 claims description 13
- 201000005569 Gout Diseases 0.000 claims description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 230000036592 analgesia Effects 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 12
- 201000008482 osteoarthritis Diseases 0.000 claims description 12
- 208000006820 Arthralgia Diseases 0.000 claims description 11
- 208000008035 Back Pain Diseases 0.000 claims description 11
- 208000005890 Neuroma Diseases 0.000 claims description 11
- 208000026137 Soft tissue injury Diseases 0.000 claims description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims description 11
- 208000004296 neuralgia Diseases 0.000 claims description 11
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 9
- 208000028389 Nerve injury Diseases 0.000 claims description 9
- 229920002125 Sokalan® Polymers 0.000 claims description 9
- 229960001631 carbomer Drugs 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 230000008764 nerve damage Effects 0.000 claims description 9
- 229920006264 polyurethane film Polymers 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 8
- 230000002980 postoperative effect Effects 0.000 claims description 8
- 206010039509 Scab Diseases 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 230000002093 peripheral effect Effects 0.000 claims description 7
- 239000002562 thickening agent Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 2
- 235000019832 sodium triphosphate Nutrition 0.000 claims description 2
- 238000010276 construction Methods 0.000 claims 1
- 238000001125 extrusion Methods 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 description 106
- 210000003491 skin Anatomy 0.000 description 95
- 238000009472 formulation Methods 0.000 description 74
- 239000010410 layer Substances 0.000 description 36
- 230000000694 effects Effects 0.000 description 27
- 239000013078 crystal Substances 0.000 description 26
- 239000000243 solution Substances 0.000 description 26
- 239000002994 raw material Substances 0.000 description 15
- 208000002847 Surgical Wound Diseases 0.000 description 13
- 239000003589 local anesthetic agent Substances 0.000 description 11
- 206010052428 Wound Diseases 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 6
- 239000004745 nonwoven fabric Substances 0.000 description 6
- 239000002313 adhesive film Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 229920002635 polyurethane Polymers 0.000 description 4
- 239000004814 polyurethane Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 239000012790 adhesive layer Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 229940060977 lidoderm Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940036950 pliaglis Drugs 0.000 description 3
- 229940019097 EMLA Drugs 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000001949 anaesthesia Methods 0.000 description 2
- 210000000544 articulatio talocruralis Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 2
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- WZSPWMATVLBWRS-UHFFFAOYSA-N 2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide;n-(2-methylphenyl)-2-(propylamino)propanamide Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C.CCN(CC)CC(=O)NC1=C(C)C=CC=C1C WZSPWMATVLBWRS-UHFFFAOYSA-N 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002192 cholecystectomy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000005135 methemoglobinemia Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- GOZBHBFUQHMKQB-UHFFFAOYSA-N trimecaine Chemical group CCN(CC)CC(=O)NC1=C(C)C=C(C)C=C1C GOZBHBFUQHMKQB-UHFFFAOYSA-N 0.000 description 1
- 229950002569 trimecaine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Anesthesiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开一种药物组合物、贴剂及其制备方法、镇痛方法、应用。该药物组合物包括单一的麻醉活性成分,麻醉活性成分包括溶解于水的麻醉活性成分和以未溶解状态存在的麻醉活性成分;麻醉活性成分在药物组合物中的质量百分比为2%以上;溶解于水的麻醉活性成分在药物组合物中的质量百分比为1%以下;麻醉活性成分为利多卡因、丁卡因、布比卡因、阿替卡因、辛可卡因、地布卡因、依替卡因、左布比卡因、甲哌卡因、丙胺卡因、罗哌卡因、三甲卡因、苯佐卡因或普鲁卡因。该药物组合物及贴剂能够获得12‑30小时的连续镇痛效果,且该贴剂能够抵抗一定外力挤压、可以保护其覆盖的配方层不被挤走,进而保持配方层的厚度。
Description
PCT国内申请,说明书已公开。
Claims (14)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810045015.8A CN110038130A (zh) | 2018-01-17 | 2018-01-17 | 药物组合物、贴剂及其制备方法、应用 |
CN2018100450158 | 2018-01-17 | ||
PCT/CN2019/071898 WO2019141178A1 (zh) | 2018-01-17 | 2019-01-16 | 药物组合物、贴剂及其制备方法、镇痛方法、应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111615383A true CN111615383A (zh) | 2020-09-01 |
Family
ID=67273063
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810045015.8A Pending CN110038130A (zh) | 2018-01-17 | 2018-01-17 | 药物组合物、贴剂及其制备方法、应用 |
CN201980008813.6A Pending CN111615383A (zh) | 2018-01-17 | 2019-01-16 | 药物组合物、贴剂及其制备方法、镇痛方法、应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810045015.8A Pending CN110038130A (zh) | 2018-01-17 | 2018-01-17 | 药物组合物、贴剂及其制备方法、应用 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20210023018A1 (zh) |
EP (1) | EP3741364A4 (zh) |
CN (2) | CN110038130A (zh) |
WO (1) | WO2019141178A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115708816A (zh) * | 2022-10-20 | 2023-02-24 | 重庆医科大学 | 一种盐酸普鲁卡因水凝胶贴膏剂及其制备方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110559275A (zh) * | 2019-08-26 | 2019-12-13 | 西安博和医疗科技有限公司 | 皮肤麻醉用敷贴及其制备方法 |
WO2024146576A1 (zh) * | 2023-01-04 | 2024-07-11 | 新领医药技术(深圳)有限公司 | 利培酮透皮施用系统及其制备方法和用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020004063A1 (en) * | 1999-09-28 | 2002-01-10 | Jie Zhang | Methods and apparatus for drug delivery involving phase changing formulations |
US20130197455A1 (en) * | 2010-03-30 | 2013-08-01 | Sparkmed Research, Llc | Drug releasing medical catheters, tubes, and devices |
CN105579003A (zh) * | 2013-07-10 | 2016-05-11 | 张洁 | 利用液体或半固体制剂持续经皮给药的工具及其使用方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9513742D0 (en) * | 1995-07-06 | 1995-09-06 | Smith & Nephew | Compositions |
JP2002193795A (ja) * | 2001-11-02 | 2002-07-10 | Yuutoku Yakuhin Kogyo Kk | 局所麻酔用テープ剤 |
US20070042027A1 (en) * | 2005-08-22 | 2007-02-22 | Haley Jeffrey T | Water soluble anesthetic in an oral patch of hydrophilic gums |
US8722065B2 (en) * | 2007-11-11 | 2014-05-13 | Medrx Co., Ltd. | Lidocaine tape preparation |
CN101966170B (zh) * | 2010-10-22 | 2012-05-02 | 鲍亚华 | 复方利多卡因贴片及其制备方法 |
ES2759582T3 (es) * | 2011-06-20 | 2020-05-11 | Hisamitsu Pharmaceutical Co | Parche que contiene lidocaína |
CN104382842A (zh) * | 2014-10-28 | 2015-03-04 | 中国人民解放军第二军医大学 | 一种内镜麻醉凝胶制剂及其应用 |
-
2018
- 2018-01-17 CN CN201810045015.8A patent/CN110038130A/zh active Pending
-
2019
- 2019-01-16 EP EP19741485.7A patent/EP3741364A4/en not_active Withdrawn
- 2019-01-16 WO PCT/CN2019/071898 patent/WO2019141178A1/zh unknown
- 2019-01-16 CN CN201980008813.6A patent/CN111615383A/zh active Pending
- 2019-01-16 US US16/962,414 patent/US20210023018A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020004063A1 (en) * | 1999-09-28 | 2002-01-10 | Jie Zhang | Methods and apparatus for drug delivery involving phase changing formulations |
US20130197455A1 (en) * | 2010-03-30 | 2013-08-01 | Sparkmed Research, Llc | Drug releasing medical catheters, tubes, and devices |
CN105579003A (zh) * | 2013-07-10 | 2016-05-11 | 张洁 | 利用液体或半固体制剂持续经皮给药的工具及其使用方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115708816A (zh) * | 2022-10-20 | 2023-02-24 | 重庆医科大学 | 一种盐酸普鲁卡因水凝胶贴膏剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
EP3741364A4 (en) | 2021-10-27 |
CN110038130A (zh) | 2019-07-23 |
EP3741364A1 (en) | 2020-11-25 |
WO2019141178A1 (zh) | 2019-07-25 |
US20210023018A1 (en) | 2021-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11338055B2 (en) | Wound dressing | |
ES2379190T3 (es) | Composición analgésica tópica | |
CN100367927C (zh) | 相变制剂的药物传递 | |
AU779570B2 (en) | Local prevention or amelioration of pain from surgically closed wounds | |
ES2452517T3 (es) | Composiciones y métodos para el tratamiento del trastorno de déficit de atención y del trastorno de déficit de atención e hiperactividad con metilfenidato | |
ES2415362T3 (es) | Agente externo para tratar heridas | |
WO2020051117A1 (en) | Cannabinoid and menthol gel compositions, patches and methods | |
US20120302640A1 (en) | Oral formulations | |
CN111615383A (zh) | 药物组合物、贴剂及其制备方法、镇痛方法、应用 | |
WO2021177940A1 (en) | Cannabinoid and menthol gel compositions, patches and methods | |
WO2020211762A1 (zh) | 脂性药物制剂及其应用 | |
US6620852B2 (en) | Topical anesthetic | |
JP2020055840A (ja) | 麻痺を伴わない疼痛緩和のための組成物および方法 | |
US7790771B1 (en) | Use of tosylchloramide(s) for treating disease of the skin, mucous membrane, organs and tissues | |
US11147775B2 (en) | Cannabinoid and menthol gel compositions, patches and methods | |
JP5796728B1 (ja) | 創傷治癒を促進し生体諸臓器の被覆(コーチング)及び庇護を目的とした生体皮膜剤。 | |
US11229610B2 (en) | Cannabinoid and menthol gel compositions, patches and methods | |
CA3038870A1 (en) | Lidocaine formulations for use in chronic open wounds | |
WO2020211787A1 (zh) | 药物制剂、含其的系统及其制备方法、应用 | |
CN118304280A (zh) | 一种复合大麻植物纤维精油缓释贴片及其制备和应用 | |
JP7450916B2 (ja) | 表面麻酔剤 | |
WO2007094413A1 (ja) | 経皮投与用医薬組成物 | |
WO2020211763A1 (zh) | 覆盖膜、含其的系统及其使用方法、应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |